Category

Industry News

Ractigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mechanism for RNA Activation in Duchenne Muscular Dystrophy Company NewsHomepage NewsIndustry NewsNews Highlight

Ractigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mechanism for RNA Activation in Duchenne Muscular Dystrophy

First clinical evidence demonstrating that a systemically delivered small activating RNA (saRNA) can safely upregulate…
Jiawei Zhou
10/03/2026
Ractigen Therapeutics to Present First-in-Human RNA Activation Data in Duchenne Muscular Dystrophy as a Late-Breaking Oral Presentation at the 31st Annual Congress of the World Muscle Society Company NewsHomepage NewsIndustry NewsNews Highlight

Ractigen Therapeutics to Present First-in-Human RNA Activation Data in Duchenne Muscular Dystrophy as a Late-Breaking Oral Presentation at the 31st Annual Congress of the World Muscle Society

Late-Breaking selection at the 31st Annual World Muscle Society Congress — a designation reserved for…
Jiawei Zhou
09/15/2026